Immunosens
Developing GLEIA, an immunoassay method to easily measure various health information.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
$709k | Early VC | ||
| Total Funding | 000k | ||
Related Content
Immunosens specializes in advanced immunoassay technology, specifically the GLEIA method, which allows for easy and precise measurement of various health data. The company serves both medical professionals and home users, providing compact and user-friendly devices that can be used in diverse settings such as examination rooms, emergency units, and home visits. Operating in the healthcare technology market, Immunosens aims to improve the quality of life by enabling better health monitoring and management. The business model revolves around the sale of their proprietary measuring devices and related consumables, generating revenue through direct sales and possibly subscription services for ongoing support and updates.
Keywords: immunoassay, GLEIA, health data, medical devices, home use, healthcare technology, compact devices, precise measurement, health monitoring, quality of life.